Hennion & Walsh Asset Management Inc. Sells 69,841 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Hennion & Walsh Asset Management Inc. decreased its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 14.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 417,833 shares of the company’s stock after selling 69,841 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.31% of Compass Pathways worth $5,912,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vivo Capital LLC bought a new position in Compass Pathways in the first quarter valued at approximately $1,106,000. Seven Fleet Capital Management LP grew its holdings in Compass Pathways by 295.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after acquiring an additional 118,021 shares during the period. BIT Capital GmbH raised its position in shares of Compass Pathways by 2,963.4% during the 4th quarter. BIT Capital GmbH now owns 288,814 shares of the company’s stock valued at $1,993,000 after acquiring an additional 279,386 shares during the last quarter. Eversept Partners LP bought a new stake in shares of Compass Pathways during the 1st quarter valued at $3,749,000. Finally, Orbimed Advisors LLC acquired a new position in shares of Compass Pathways in the 1st quarter valued at $6,363,000. 46.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CMPS has been the topic of several recent research reports. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target on the stock in a research report on Wednesday, July 8th. Compass Point set a $25.00 price objective on Compass Pathways in a report on Tuesday, July 7th. Wells Fargo & Company assumed coverage on Compass Pathways in a research note on Monday, July 27th. They issued an “equal weight” rating and a $13.00 target price on the stock. Oppenheimer restated an “outperform” rating on shares of Compass Pathways in a report on Wednesday. Finally, Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Compass Pathways currently has an average rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Stock Performance

CMPS opened at $13.54 on Monday. The firm’s fifty day moving average is $12.59 and its two-hundred day moving average is $9.35. The firm has a market cap of $1.83 billion, a PE ratio of -2.93 and a beta of 2.50. Compass Pathways PLC Sponsored ADR has a twelve month low of $3.97 and a twelve month high of $15.40. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.25 EPS for the current year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.